NCT02657434 is a Phase 3 clinical trial of Atezolizumab in Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT02657434?

NCT02657434 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT02657434?

Interventions in NCT02657434: Atezolizumab, Carboplatin, Cisplatin, Pemetrexed.

What condition does NCT02657434 study?

NCT02657434 studies Non-Small Cell Lung Cancer.

Is NCT02657434 still recruiting?

NCT02657434 is currently completed. Last updated 21 November 2023.

Are results published for NCT02657434?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-11-21 · How we verify

NCT02657434

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Completed Phase 3 Results posted Last updated 21 November 2023

What this trial tests

Phase 3 trial testing Atezolizumab in Non-Small Cell Lung Cancer in 578 participants. Completed in 13 December 2022.

Timeline

30 April 2016

Primary endpoint
18 July 2019

13 December 2022

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	578
Start date	30 April 2016
Primary completion	18 July 2019
Estimated completion	13 December 2022
Sites	183 locations across Italy, Japan, Malaysia, Taiwan, Ireland, South Korea, Netherlands, Russia

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Pemetrexed — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Primary · Randomization up to approximately 39 months

PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first.

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	5.2	4.3 – 5.6
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	7.7	6.7 – 8.5

Overall Survival (OS) Primary · Randomization up to approximately 39 months

OS is defined as time from randomization to death from any cause.

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	13.6	11.0 – 15.7
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	17.5	13.2 – 19.6

Overall Survival Rate at Year 1 Secondary · Year 1

The Overall Survival Rate at the 1-year landmark time point is defined as the probabilities that participants are alive 1-year after randomization.

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	55.04	49.21 – 60.87
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	59.72	54.02 – 65.41

Overall Survival Rate Year 2 Secondary · Year 2

The Overall Survival Rate at the 2-year landmark time point is defined as the probabilities that participants are alive 2-years after randomization.

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	34.01	28.40 – 39.62
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	39.13	33.44 – 44.81

Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 Secondary · Randomization up to approximately 25 months

An objective response is defined as either an unconfirmed CR or a PR, as determined by the investigator using RECIST v1.1. Objective Response Rate is defined as the proportion of patients who had an objective response.

Responders

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	37.4
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	51.7

Non-Responders

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	62.6
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	48.3

Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 Secondary · Randomization up to approximately 25 months

DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first.

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	6.4	4.4 – 7.6
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	9.5	6.9 – 12.2

Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Secondary · Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for

Dyspnoea: Week 3

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-1.95	± 23.97
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-1.39	± 25.17

Dyspnoea: Week 6

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-1.23	± 23.16
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-4.71	± 26.66

Dyspnoea: Week 9

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	0.20	± 26.34
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-6.33	± 26.62

Dyspnoea: Week 12

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-0.91	± 27.57
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-3.39	± 29.10

Dyspnoea: Week 15

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-1.67	± 28.92
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-2.44	± 28.73

Dyspnoea: Week 18

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-2.12	± 24.85
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-3.44	± 30.43

Dyspnoea: Week 21

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-5.67	± 29.61
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-2.89	± 31.83

Dyspnoea: Week 24

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-2.75	± 28.74
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-2.45	± 31.85

Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Secondary · Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

The EORTC QLQ-LC13 module incorporates one multiple item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or ite

Coughing: Week 3

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-2.50	± 25.37
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-3.41	± 26.90

Coughing: Week 6

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-3.57	± 27.20
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-9.82	± 26.50

Coughing: Week 9

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-1.85	± 24.43
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-8.29	± 31.37

Coughing: Week 12

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-3.91	± 28.46
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-10.71	± 31.66

Coughing: Week 15

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-6.33	± 30.39
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-11.53	± 29.05

Coughing: Week 18

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-4.00	± 26.97
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-11.63	± 27.92

Coughing: Week 21

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-6.00	± 27.78
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-10.50	± 30.76

Coughing: Week 24

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-4.81	± 28.05
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-10.03	± 33.08

Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Secondary · Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \& 2, 'Cough' score is mean of question 3 \& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questi

Chest Pain: Week 1

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	0.20	± 0.83
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	0.30	± 0.88

Chest Pain: Week 2

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-0.01	± 0.88
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	0.21	± 0.85

Chest Pain: Week 3

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-0.05	± 0.92
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	0.06	± 0.95

Chest Pain: Week 4

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	0.03	± 0.91
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	0.03	± 0.93

Chest Pain: Week 5

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-0.02	± 0.93
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-0.01	± 0.88

Chest Pain: Week 6

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	-0.05	± 0.88
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-0.02	± 0.92

Chest Pain: Week 7

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	0.07	± 1.00
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-0.04	± 1.00

Chest Pain: Week 8

Group	Value	95% CI
Arm B (Carboplatin or Cisplatin + Pemetrexed)	0.03	± 0.94
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	-0.07	± 1.02

Minimum Observed Serum Atezolizumab Concentration (Cmin) Secondary · Predose (Prd; 0 hour [h]) on D1 of Cy 2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle (up to approximately 25 months)

Minimum observed serum atezolizumab concentration (Cmin) prior to infusion at selected cycles (Arm A)

Cy2D1

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	69.8	± 32.3

Cy3D1

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	115	± 51.5

Cy4D1

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	151	± 69.9

Cy8D1

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	221	± 101

Cy16D1

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	234	± 86.7

Cy24D1

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	257	± 95.1

Treatment Discontinuation Visit

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	129	± 93.1

Day 120 Post Last Dose

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	13.4	± 19.4

Maximum Observed Serum Atezolizumab Concentration (Cmax) Secondary · Day 1 of Cycle 1 (Cycle length=21 days)

Maximum observed serum atezolizumab concentration (Cmax) after infusion (Arm A)

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	403	± 118

Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) Secondary · Prd (0 h), 5-10 minutes (mins) before end of carboplatin infusion (infusion duration=1-2 h), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)

Cy1D1 Predose

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	NA	± NA

Cy1D1 Before End of Infusion

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	14900	± 4260

Cy1D1 Post Infusion

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	12800	± 4470

Cy3D1 Predose

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	220	± 83.8

Cy3D1 Before End of Infusion

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	17900	± 4390

Cy3D1 Post Infusion

Group	Value	95% CI
Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	13900	± 4080

Adverse events — posted to ClinicalTrials.gov

Time frame: From the first study drug to the data cutoff date: 13 December 2022 (up to approximately 80 months).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm B (Carboplatin or Cisplatin + Pemetrexed)

Serious: 91/274 (33%)

Deaths: 189/286

Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed

Serious: 149/291 (51%)

Deaths: 190/292

Serious adverse events (186 terms)

Reaction	System	Arm B (Carboplatin or Cisp…	Arm A (Atezolizumab + Carb…
PNEUMONIA	Infections and infestations	—	—
FEBRILE NEUTROPENIA	Blood and lymphatic system disorders	—	—
PYREXIA	General disorders	—	—
ANAEMIA	Blood and lymphatic system disorders	—	—
THROMBOCYTOPENIA	Blood and lymphatic system disorders	—	—
DIARRHOEA	Gastrointestinal disorders	—	—
PNEUMONITIS	Respiratory, thoracic and mediastinal disorders	—	—
VOMITING	Gastrointestinal disorders	—	—
RESPIRATORY TRACT INFECTION	Infections and infestations	—	—
URINARY TRACT INFECTION	Infections and infestations	—	—
ASTHENIA	General disorders	—	—
PANCYTOPENIA	Blood and lymphatic system disorders	—	—
ABDOMINAL PAIN	Gastrointestinal disorders	—	—
SEPSIS	Infections and infestations	—	—
DEHYDRATION	Metabolism and nutrition disorders	—	—
CEREBROVASCULAR ACCIDENT	Nervous system disorders	—	—
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	—	—
NEUTROPENIA	Blood and lymphatic system disorders	—	—
GENERAL PHYSICAL HEALTH DETERIORATION	General disorders	—	—
CELLULITIS	Infections and infestations	—	—
INFLUENZA	Infections and infestations	—	—
ALANINE AMINOTRANSFERASE INCREASED	Investigations	—	—
BLOOD CREATININE INCREASED	Investigations	—	—
NEUTROPHIL COUNT DECREASED	Investigations	—	—
PLATELET COUNT DECREASED	Investigations	—	—

Other adverse events (50 terms — click to expand)

Reaction	System	Arm B (Carboplatin or Cisp…	Arm A (Atezolizumab + Carb…
ANAEMIA	Blood and lymphatic system disorders	—	—
NAUSEA	Gastrointestinal disorders	—	—
CONSTIPATION	Gastrointestinal disorders	—	—
ASTHENIA	General disorders	—	—
DECREASED APPETITE	Metabolism and nutrition disorders	—	—
FATIGUE	General disorders	—	—
DIARRHOEA	Gastrointestinal disorders	—	—
PYREXIA	General disorders	—	—
VOMITING	Gastrointestinal disorders	—	—
ALANINE AMINOTRANSFERASE INCREASED	Investigations	—	—
ASPARTATE AMINOTRANSFERASE INCREASED	Investigations	—	—
NEUTROPENIA	Blood and lymphatic system disorders	—	—
NEUTROPHIL COUNT DECREASED	Investigations	—	—
OEDEMA PERIPHERAL	General disorders	—	—
ARTHRALGIA	Musculoskeletal and connective tissue disorders	—	—
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	—	—
COUGH	Respiratory, thoracic and mediastinal disorders	—	—
RASH	Skin and subcutaneous tissue disorders	—	—
BACK PAIN	Musculoskeletal and connective tissue disorders	—	—
THROMBOCYTOPENIA	Blood and lymphatic system disorders	—	—
PLATELET COUNT DECREASED	Investigations	—	—
STOMATITIS	Gastrointestinal disorders	—	—
HEADACHE	Nervous system disorders	—	—
BLOOD CREATININE INCREASED	Investigations	—	—
WHITE BLOOD CELL COUNT DECREASED	Investigations	—	—
PRURITUS	Skin and subcutaneous tissue disorders	—	—
DYSGEUSIA	Nervous system disorders	—	—
INSOMNIA	Psychiatric disorders	—	—
WEIGHT DECREASED	Investigations	—	—
DIZZINESS	Nervous system disorders	—	—
MUCOSAL INFLAMMATION	General disorders	—	—
PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	—	—
CHEST PAIN	General disorders	—	—
HYPOKALAEMIA	Metabolism and nutrition disorders	—	—
DRY SKIN	Skin and subcutaneous tissue disorders	—	—
HYPOMAGNESAEMIA	Metabolism and nutrition disorders	—	—
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	—	—
HYPOTHYROIDISM	Endocrine disorders	—	—
LACRIMATION INCREASED	Eye disorders	—	—
CONJUNCTIVITIS	Infections and infestations	—	—

Most-reported serious reactions: PNEUMONIA, FEBRILE NEUTROPENIA, PYREXIA, ANAEMIA, THROMBOCYTOPENIA, DIARRHOEA, PNEUMONITIS, VOMITING.

Data from ClinicalTrials.gov NCT02657434 adverse events section.

Sponsor's own description

This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors: recent progress and potential biomarkers.
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. · · 2018 · cited 1495× · PMID 30546008 · DOI 10.1038/s12276-018-0191-1
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, et al · · 2017 · cited 1206× · PMID 28878676 · DOI 10.3389/fphar.2017.00561
Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, et al · · 2023 · cited 737× · PMID 36810079 · DOI 10.1186/s12943-023-01740-y
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y, Kumar AB, Finnes H, Markovic SN, et al · · 2018 · cited 163× · PMID 30100909 · DOI 10.3389/fimmu.2018.01739
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Socinski MA, Jotte RM, Cappuzzo F, Nishio M, et al · · 2023 · cited 148× · PMID 36795388 · DOI 10.1001/jamaoncol.2022.7711
Current state of immunotherapy for non-small cell lung cancer.
Malhotra J, Jabbour SK, Aisner J. · · 2017 · cited 147× · PMID 28529902 · DOI 10.21037/tlcr.2017.03.01
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Onoi K, Chihara Y, Uchino J, Shimamoto T, et al · · 2020 · cited 137× · PMID 32384677 · DOI 10.3390/jcm9051362

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02657434 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 21 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02657434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing